Synaptogenix, Inc. (SYN) is a biotechnology company focused on researching and developing therapeutic approaches for neurodegenerative diseases, such as Alzheimer's disease. The company is dedicated to discovering and developing drug candidates that could impact the pathological processes associated with these diseases. Their research centers around mechanisms related to amyloid and tau proteins, which are characteristic of Alzheimer's disease. Synaptogenix aims to bring forth new approaches to treatment and slowing the progression of progressive neurodegenerative damage. Investors interested in drug development for neurodegenerative diseases and innovations in the field of neurology might see potential in Synaptogenix, Inc. (SYN) shares for progress and growth in this domain.
Feed
There are no posts to show right now.
Używamy ciasteczek, aby ulepszyć Twoje doświadczenie na naszej stronie.
